Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-eluting stents: current issues.

Andrew T L Ong1, Patrick W Serruys

  • 1Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.

Texas Heart Institute Journal
|January 6, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Macrotroponin: A Case Series and Review of the Literature.

Heart, lung & circulation·2025
Same author

Trends in Modifiable Risk Factors Amongst First Presentation ST Elevation Myocardial Infarction Patients in a Large Longitudinal Registry.

Heart, lung & circulation·2023
Same author

Low Incidence of Ischemic Stroke Associated With Thrombus Aspiration in STEMI Patients Undergoing Primary PCI.

The Journal of invasive cardiology·2021
Same author

Considerations for Treating Patients With Chronic Total Occlusion of Coronary Arteries.

Heart, lung & circulation·2019
Same author

Transcatheter versus surgical aortic valve replacement: a systematic review and meta-analysis of randomised and non-randomised trials.

Open heart·2014
Same author

Quantification of scientific output in cardiovascular medicine: a perspective based on global data.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2013

Drug-eluting stents show similar early thrombosis rates to bare-metal stents but pose a higher risk for late stent thrombosis. Caution is advised when discontinuing antiplatelet therapy after drug-eluting stent implantation.

Area of Science:

  • Cardiovascular medicine
  • Interventional cardiology
  • Biomedical engineering

Background:

  • Drug-eluting stents (DES) are widely used to prevent restenosis after percutaneous coronary intervention.
  • While effective, concerns remain regarding stent thrombosis, particularly late stent thrombosis.

Purpose of the Study:

  • To compare the incidence of early and late stent thrombosis between drug-eluting stents and bare-metal stents.
  • To discuss the implications of neointima formation and antiplatelet therapy cessation in patients with DES.

Main Methods:

  • Review of existing literature and clinical trial data on stent thrombosis rates.
  • Analysis of neointima formation patterns associated with different stent types.

Main Results:

Related Experiment Videos

  • Early stent thrombosis rates for DES (1%-1.5%) are comparable to bare-metal stents.
  • Late stent thrombosis incidence for DES is at least 0.35%, representing a significant concern.
  • Neointima formation continues to grow with DES, unlike bare-metal stents where it may regress.

Conclusions:

  • Late stent thrombosis is a critical consideration for drug-eluting stents, necessitating careful management of antiplatelet therapy.
  • Further research and clinical trials are ongoing to determine the optimal DES and compare them with surgical interventions.